Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 15, 2019 - Issue
Submit an article Journal homepage
181
Views
3
CrossRef citations to date
0
Altmetric
Review

Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis

Hans-Klaus GoischkeIndependent Research, Internal Medicine, Rehabilitation Medicine, Social Medicine, Bad Brückenau, Bavaria, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5192-4348
ORCID Icon
Pages 891-904 | Published online: 12 Jul 2019

References

  • Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014;99(1):80–90. doi:10.1210/jc.2013-220124170099
  • Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab therapy for multiple sclerosis. JAMA Neurol. 2017;74:907–908. doi:10.1001/jamaneurol.2017.0325 28604941
  • Ranganathan U, Kaunzer U, Foster S, Vartanian T, Perumal JS. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis. Mult Scler. 2018;24(4):540–542. doi:10.1177/135245851769987628287030
  • Puthenparampil M, Rinaldi F, Federle L, Cazzola C, Perini P, Gallo P. Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinical silent phenomenon. Ther Adv Neurol Disord. 2018;11 Publ online. doi:10.1177/1756285617741056
  • Yap SM, McNicholas N, Hutchinson M, McGuigan C. Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis – not always self-limiting, fully reversible or predictable. Mult Scler. 2018;24(4):552–553. doi:10.1177/135245851771915128661220
  • Meunier B, Rico A, Seguier J, et al. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Mult Scler. 2018;25:1–3. doi:10.1177/1352458517729766
  • Di Ioia M, Farina D, Di Tommaso V, et al. Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis. Mult Scler. 2018;24:813–815. doi:10.1177/135245851774309329359617
  • Barcellini W. New insights in the pathogenesis of autoimmune hemolytic anemia. Trans Med Hemother. 2015;42(5):287–293. doi:10.1159/000439002
  • Perga S, Martire S, Montarolo F, et al. The footprints of poly-autoimmunity: evidence for common biological factors involved in multiple sclerosis and hashimoto thyroiditis. Front Immunol. 2018;9:311. doi:10.3389/fimmu.2018.00311 29527211
  • Azzopardi L, Thompson SA, Harding KE, et al. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:795–798. doi:10.1136/jnnp-2013-30704224368840
  • Obermann M, Ruck T, Pfeuffer S, Baum J, Wiendl H, Meuth SG. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting- multiple sclerosis. Mult Scler. 2016;22(9):1235–1241. doi:10.1177/135245851663855826980848
  • Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118(24):6299–6305. doi:10.1182/blood-2011-08-37113821960587
  • Fattizzo B, Zaninoni A, Gianotta JA, Binda F, Cortelezzi A, Barcellini W. Reduced 25-OH vitamin D in patients with autoimmune cytopenias, clinical correlations and literature review. Autoimmun Rev. 2016;15:770–775. doi:10.1016/j.autrev.2016.03.015 26988993
  • Culic S, Markic J, Petrovic D, Konjevoda P, Pavelic J. Serum vitamin D levels in children with newly diagnosed and chronic immune thrombocytopenia. Semin Hematol. 2016;53(Suppl 1):S67–S69. doi:10.1053/j.seminhematol.2016.04.02027312171
  • Zhang Q, Bai H, Wang W. Increased percentages of T cells producing interleukn-21 in patients with immune thrombocytopenic purpura. Cell Biol Int. 2014;38(4):520–525. doi:10.1002/cbin.1022024323496
  • Hu Y, Wang X, Yu S, Hou Y, Ma D, Hou M. Neutralizations of IL-17A and IL-21 regulate regulatory T cell/T-helper 17 imbalance via T-helper 17-associated signaling pathway in immune thrombocytopenia. Expert Opin Ther Targets. 2015;19(6):723–732. doi:10.1517/14728222.2015.1016499 25976230
  • Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119(7):2052–2061. doi:10.1172/JCI3787819546505
  • Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59(6):881–886. doi:10.2310/JIM.0b013e31821b8755
  • Almerighi C, Sinistro A, Ciaprini C, Rocchi G, Bergamini A. 1Alpha,25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine. 2009;45(3):190–197. doi:10.1016/j.cyto.2008.12.009 19186073
  • Jeffery LE, Burke F, Mura M, et al. 1,25-dihydroxyvitamin D3 and interleukin-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183(9):5458–5467. doi:10.4049/jimmunol.080321719843932
  • Kulling PM, Olson KC, Olson T, Feith DJ, Loughran T. Vitamin D in hematological disorders and malignancies. Eur J Haematol. 2017;98(3):187–197. doi:10.1111/ejh.1281827743385
  • Bockow B, Bockow-Kaplan T. Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports. J Med Case Rep. 2013;7:91. doi:10.1186/1752-1947-7-9123556539
  • Schwalfenberg GK. Solar radiation and vitamin D: mitigating environmental factors in autoimmune disease. J Environ Publ Health. 2012. doi:10.1155/2012/619381
  • Liu W, Li H, Hao Y, et al. Decreased immunosuppressive actions of 1-Alpha-25-dihydroxyvitamin D3 in patients with immune thrombocytopenia. Mol Immunol. 2016;78:89–97. doi:10.1016/j.molimm.2016.08.014 27614264
  • Guo B. IL-10 modulates Th17 pathogenicity during autoimmune diseases. J Clin Cell Immunol. 2016;7(2):400. doi:10.4172/2155-989927308096
  • Ray A, Wang L, Dittel BN. IL-10-independent regulatory B-cell subsets and mechanisms of action. Int Immunol. 2015;27(10):531–536. doi:10.1093/intimm/dxv03325999596
  • Muraro PA, Scolding NJ, Fox RJ. Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance. Neurology. 2018;90:819–820. doi:10.1212/WNL.000000000000540929602911
  • Pierrot-Deseilligny C, Souberbielle JC. Vitamin D and multiple sclerosis: an update. Mult Scler Relat Dis. 2017;14:35–45. doi:10.1016/j.msard.2017.03.014
  • Winter FD Jr. Immune thrombocytopenia associated with consumption of tonic water. Proc (Bayl Univ Med Cent). 2015;28(2):213–216. doi:10.1080/08998280.2015.1192923325829658
  • Rieckmann P, Lenz A, Hoffmann M, Poske U, Behr K, Kallmann B. Fatal autoimmune hemolytic anemia associated with alemtuzumab in a MS patient with severe relapsing remitting disease course and prior immune therapies. Neurology. 2016;86:P2.103.
  • Reddel SW, Barnett MH, Riminton S, Dugal T, Buzzard K, Wang CT. Successful implementation of an automated electronic support system for patient safety monitoring: the alemtuzumab in multiple sclerosis safety systems (AMS3) study. Mult Scler. 2018; Epub ahead of print. doi:10.1177/1352458518783673
  • Saarela M, Senthil K, Jones J, et al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018;90:849–851. doi:10.1212/WNL.000000000000542029602914
  • Croteau D, Flowers C, Kulick CG, et al. Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab. Neurology. 2018;90:e1548–e1552. Epub ahead of print. doi:10.1212/WNL.000000000000542229602912
  • Zimmermann J, Buhl T, Müller M. Alopecia universalis following alemtuzumab treatment in multiple sclerosis: a barely recognized manifestation of secundary autoimmunity-report of a case and review of the literature. Front Neurol. 2017. doi:10.3389/fneur.2017:00569
  • Leussink VI, Reifenberger J, Hartung HP. Case of alopecia universalis associated with alemtuzumab treatment in MS. Neurol Neuroimmunol Neuroinflamm. 2018;5:e454. doi:10.1212/NXI.0000000000000454
  • Spano F, Donovan JC. Alopecia areata: part I: pathogenesis, diagnosis, and prognosis. Can Fam Physician. 2015;61:751–755.26371097
  • Saif GAB. Severe subtype of alopecia areata is highly associated with thyroid autoimmunity. Saudi Med J. 2016;37:656–661. doi:10.15537/Smj.2016.6.1377727279512
  • Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20:1055–1060. doi:10.1111/j.1468-3083.2006.01676.x16987257
  • Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049. doi:10.1038/nm.364525129481
  • Wang ECE, Christiano AM. The changing landscape of alopecia areata: the translational landscape. Adv Ther. 2017;34(7):1586–1593. doi:10.1007/s12325-017-0540-928646392
  • Bhat YJ, Latif I, Malik R, et al. Vitamin D level in alopecia areata. Indian J Dermatol. 2017;62(4):407–410. doi:10.4103/ijd.IJD_677_16 28794553
  • Lee S, Kim BJ, Lee CH, Lee WS. Increased prevalence of vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(7):1214–1221. doi:10.1111/jdv.1498729633370
  • Bakry OA, Farargy SME, Shafiee MKE, Soliman A. Serum Vitamin D in patients with alopecia areata. Indian Dermatol Online J. 2016;7(5):371–377. doi:10.4103/2229-5178.19050427730032
  • Chan JK, Traboulsee AL, Sayao AL. Case of alemtuzumab-related alopecia areata management in MS. Neurol Neuroimmunol Neuroinflamm. 2019;6(1):e516. doi:10.1212/NXI.000000000000051630568994
  • Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: longterm safety and efficacy. J Neurol Neurosurg Psychiatry. 2015;86:208–215. doi:10.1136/jnnp-2014-30772124849515
  • Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77:573–579. doi:10.1212/WNL.0b013e318228bec521795656
  • CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N Engl J Med. 359;2008:1786–1801. doi:10.1056/NEJMoa080193618946064
  • Samuels MH. Subacute, silent, and postpartum thyroiditis. Med Clin North Am. 2012;96:223–233. doi:10.1016/j.mcna.2012.01.00322443972
  • Rotondi M, Molteni M, Leporati P, Capelli V, Marino M, Chiovato L. Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response. Front Endocrinol (Lausanne). 2017;8:254. doi:10.3389/fendo.2017.0025429033895
  • Pariani N, Willis M, Muller I, et al. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab. 2018 Epub ahead of print. doi:10.1210/jc.2018-00359
  • Mahzari M, Arnaout A, Freedman MS. Alemtuzumab induced thyroid disease in multiple sclerosis: a review and approach to management. Can J Neurol Sci. 2015;42:284–291. doi:10.1017/cjn.2015.4825990097
  • Bizzaro G, Shoenfeld Y. Vitamin D and autoimmune thyroid diseases: facts and unresolved questions. Immun Res. 2015;61:46–52. doi:10.1007/s12026-014-8579-z
  • Ma J, Wu D, Li C, et al. Lower serum 25-hydroxyvitamin D level is associated with 3 types of autoimmune thyroid diseases. Medicine (Baltimore). 2015;94:e1639. doi:10.1097/MD.000000000000087426426654
  • Kivity S, Agmon-Levin N, Zisappl M, et al. Vitamin D and autoimmune thyroid disease. Cell Mol Immunol. 2011;8:243–247. doi:10.1038/cmi.2010.7321278761
  • Tamer G, Arik S, Tamer I, Coksert D. Relative vitamin D insufficiency in Hashimotoʼs thyroiditis. Thyroid. 2011;21:891–896. doi:10.1089/thy.2009.020021751884
  • Mackawy AM, Al-Ayed BM, Al-Rashidi BM. Vitamin D deficiency and its association with thyroid disease. Int J Health Sci (Qassim). 2013;7:267–275. doi:10.12816/000605424533019
  • Wang X, Zynat J, Guo Y, et al. Low serum vitamin D is associated with anti-thyroid-globulin antibody in female individuals. Int J Endocrinol. 2015;2015:1–6. doi:10.1155/2015/285290
  • Goswami R, Marwaha RK, Gupta N, et al. Prevalence of vitamin D deficiency and its relationships with thyroid autoimmunity in Asian Indians: a community-based survey. Br J Nutr. 2009;102:382–386. doi:10.1017/S000711450922082419203420
  • Chailurkit LO, Aekplakorn W, Ongphiphadhanakul B. High vitamin D status in younger individuals is associated with low circulation thyrotropin. Thyroid. 2013;23:25–30. doi:10.1089/thy.2012.000122931506
  • Smolders J, Hupperts R, Vieth R, et al. High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with RRMS receiving subcutaneous interferon ß1a. 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 9 14–17, 2016; London Free communications1; Abstract 166: 09-16-2016, ECTRIMS online library147013.
  • Baker D, Giovannoni G, Schmierer K. Marked Neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment. Mult Scler Relat Disord. 2017;18:181–183. doi:10.1016/j.msard.2017.09.02829141806
  • Gaitán MI, Ysrraelit MC, Correale J. Neutropenia in patient with multiple sclerosis treated with alemtuzumab. JAMA Neurol. 2017;74(9):1143–1144. doi:10.1001/jamaneurol.2017.145628715536
  • Galgani S, Prosperini L, Haggiag S, Tortorella C, Gasperini C. Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report. J Neurol. 2018;265:2152–2153. doi: 10/1007/s00415-018-8976-730019085
  • Yiannopoulou KG, Papadimitriou D, Anastasiou AI, Siakantaris M. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion. Mult Scler Relat Disord. 2018;23:15–16. doi:10.1016/j.msard.2018.04.01429730587
  • Willis MD, Harding KE, Pickersgill TP, et al. Alemtuzumab for multiple sclerosis: long term follow-up in an multi-centre cohort. Mult Scler. 2016;22(9):1215–1223. doi:10.1177/135245851561409226514979
  • Malmeström C, Andersson BA, Lycke J. First reports case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. J Neurol. 2014;261:2016–2018. doi:10.1007/s00415-014-7448-y25082626
  • Richter S, Wagner B, Gulowsden-Celius E. Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis another probable secondary autoimmune disease. J Neurology. 2019;266:1270–1271. doi:10.1007/s00415-019-09257-5
  • Maddaloni E, Cavallari I, Napoli N, Conte C. Vitamin D and diabetes mellitus. Front Horm Res. 2018;50:161–176. doi:10.1159/00048608329597238
  • Norris JM, Lee HS, Frederiksen B, et al. Plasma 25-hydroxyvitamin d concentrationen and risk of Islet autoimmunitiy. Diabetes. 2017. doi:10.2337/db17-0802
  • Bizzaro G, Antico A, Fortunato A, Bizzaro N. Vitamin D and autoimmune diseases: is vitamin D receptor (VDR) polymorphismus the culprit? IMAJ. 2017;19:438–443.28786260
  • Weydert JA. Vitamin D in children`s health. Children (Basel). 2014;1(2):208–226. doi:10.3390/children102020827417476
  • Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of Vitamin D and risk of type1 diabetes: a birth-cohort study. Lancet. 2001;358:1500–1503. doi:10.1016/S0140-6736(01)06580-111705562
  • Gorham ED, Garland CF, Burgi AA, et al. Lower prediagnostic serum 25-hydroxyvitamin D concentration is associated with higher risk of insulin-requiring diabetes: a nested case–control study. Diabetologia. 2012;55(12):3224–3227. doi:10.1007/s00125-012-2709-822955995
  • Talaat IM, Nasr A, Alsulaimani AA, et al. Association between type 1, type 2 cytokines, diabetic autoantibodies and 25-hydroxyvitamin d in children with the type 1 diabetes. J Endocrinol Invest. 2016;39(12):1425–1434. doi:10.1007/s40618-016-0514-927541155
  • Hoffman BM, Zeid NA, Alam U, Caress JB. Lambert-Eaton myasthenic syndrom associated with alemtuzumab. Mult Scler Relat Disord. 2019;27:131–132. doi:10.1016/j.msard.2018.10.01530384197
  • Kang SY, Kang JH, Choi JC, Song SK, Oh JH. Low serum vitamin D levels in patients with myasthenia gravis. J Clin Neurosci. 2018;50:294–297. doi:10.1016/j.jocn.2018.01.04729396067
  • Cadegiani FA. Remission of severe myasthenia gravis after massive-dose vitamin D treatment. Am J Case Rep. 2016;17:51–54. doi:10.12659/ajcr.89484926822380
  • Sankari E, Dahlqvist G, Laurent M, van Pesch V. Auto-immune hepatitis in a patients with multiple sclerosis treated with alemtuzumab. Acta Neurol Belg. 2018;118:331–333. doi:10.1007/s13760-018-0922-z29713905
  • Carlson A, Bozinov N, Kipp L, Dunn J, Lock C. Autoimmune hepatitis during treatment of multiple sclerosis with alemtuzumab (P5.350). Neurology. 2018;90(15 Suppl.). doi:10.1212/WNL.0000000000005560
  • Canham LJW, Mozayani B, Chelvaratnam U, et al. The first reported case of autoimmune hepatitis following alemtuzumab therapy for multiple sclerosis. ECTRIMS Online Library. 2017:199783 Abstract:ePoster1763.
  • De Seze J, Delcambre C, Fajardy I, et al. autoimmune hepatitis and multiple sclerosis: a coincidental association? Mult Scler. 2005;11:691–693. doi:10.1191/1352458505ms1239oa16320729
  • Strassburg C, Beckebaum S, Geier A, et al. Practice guideline autoimmune liver diseases. Z Gastroenterol. 2017;55:1135–1226. doi:10.1055/s-0043-12019929141269
  • Beattie W, Yan B, Sood S. Acute severe hepatitis with alemtuzumab and rechallenge after a year. J Clin Neurosci. 2019;60:158–160. doi:10.1016/j.jocn.2018.10.05530348589
  • Bresteacu C, Prevot S, Perlemuter G, Voican C. Methylprednisolone-induced acute liver injury in a patient treated for multiple sclerosis relapse. BMJ Case Rep. 2018;5. In Press. doi:10.1136/bcr-2017-223670
  • Nociti V, Biolato M, De Fino C, et al. Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. Brain Behav. 2018;8(6):e00968. doi:10.1002/brb3.96829729087
  • Cacao G, Santos E, Martins Silva A. Concurrent autoimmune hepatitis in multiple sclerosis. Mult Scler. 2018;24(3):350–353. doi:10.1177/135245851769288528273779
  • Beinhardt S, Eder M, Marculescu A, et al. High prevalence of vitamin D deficiency in patients with autoimmune hepatitis: impact on clinical presentation and response to treatment. Z Gastroenterol. 2015;53:P61. doi:10.1055/s-0035-1551749
  • Efe C, Kav T, Aydin C, et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. Dig Dis Sci. 2014;59(12):3035–3042. doi:10.1007/s10620-014-3267-325002309
  • Czaja AJ, Montano-Loza AJ. Evolving role of vitamin D in immune-mediated disease and its implications in autoimmune hepatitis. Dig Dis Sci. 2019;64(2):324–344.30370494
  • Ebadi M, Bhanji RA, Mazurak VC, Lytvyak E, Mason A, Czaja AJ. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. Aliment Pharmacol Ther. 2019;49(2):173–182. doi:10.1111/apt.1502930484857
  • Imga NN, Efe C. Editorial: the role of vitamin D in autoimmune hepatitis. Aliment Pharmacol Ther. 2019;40:342. doi:10.1111/apt.15075
  • O´Connel K, Kelly S, Kinsella K, et al. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized duble-blind- placebo-controlled trial. Trials. 2013;14:272. doi:10.1186/1745-6215-14-27223981773
  • Breuer J, Loser K, Mykicki N, Wiendl H, Schwab N. Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D? J Neuroimmunol. 2018. doi:10.1016/j.jneuroim.2018.05.006
  • McCaughan G, Massey J, Sutton I, Curnow J. Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis. BMJ Case Rep. 2017. doi:10.1136/bcr-2017-223016
  • Pisa M, Della Valle P, Coluccia A, et al. Acquired haemophilia A as a secondary auatoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report. Mult Scler Rel Disord. 2019;27:403–405. doi:10.1016/j.msard.2018.11.029
  • Madeley J, Hodges G, Birchley A. Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: a case report. BMJ Case Rep. 2018. doi:10.1136/bcr-2018-226588
  • Giarola B, Massey J, Barnett Y, Rodrigues M, Sutton I. Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis. Mult Scler Relat Disord. 2019;28:31–33. doi:10.1016/j.msard.2018.12.00430553166
  • Metz I, Rieckmann P, Kallmann B, Brück W. Disseminated necrotizing leukoencephalopathy eight month after alemtuzumab treatment for multiple sclerosis. Acta Neuropathol Commun. 2016;4:81. doi:10.1186/s40478-015-0253-827503238
  • Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, et al. Vitiligo after alemtuzumab treatment. Secondary autoimmunity is not all about B cells. Neurology. 2018;91(24). doi:10.1212/WNL.0000000000005773
  • Eichau S, Lopez-Ruiz R, Ruiz-Pena JL, et al. Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab. Rev Neurol. 2018;66:395–396.29790573
  • Upala S, Sanguankeo A. Low 25-hydroxyvitamin D levels are associated with vitiligo: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2016;32(4):181–190. doi:10.1111/phpp.1224127005676
  • Aly D, Mohammed F, Sayed K, et al. Is there a relation between vitamin D and interleukin-17 in Vitiligo? A cross-sectional study. Dermatology. 2017;233(6):413–418. doi:10.1159/00047992528954273
  • Zhou L, Shi YL, Li K, et al. Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non segmental vitiligo development. Pigment Cell Melanoma Res. 2015;28(3):324–329. doi:10.1111/pcmr.1235525604047
  • Finamor DC, Coimbra RS, Neves LCM, et al. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin on the clinical course of vitiligo and psoriasis. Dermatoendocrinol. 2013;5(1):222–234. doi:10.4161/derm.2480824494059
  • Aoud P, Yiannakis C, Fernando SL, Parratt J. A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis. Mult Scler Expert Translat Clinic. 2018. doi:10.1177/2055217318819012
  • Azali P, Helmers B, Kockum I, et al. Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann Rheum Dis. 2013;72(4):512–516. doi:10.1136/annrheumdis-2012-20184922993226
  • Silva MG, Oba-Shinjo SM, Marie SKN, Shinjo SK. Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis. Clin Exp Rheumatol. 2018 Epub ahead of print. PMID:30620283
  • Tyshkov C, Pawate S, Bradshaw MJ, et al. Multiple sclerosis and sarcoidosis. A case for coexistence. Neurol Clin Pract. 2019;9:218–227. doi:10.1212/CPJ.0000000000000629
  • Reves-Mantilla M, Kimbrough DJ, Calabresi PA, Pardo-Villamizar CA. The systematic sarcoidosis and multiple sclerosis dilemma. ECTRIMS online-library.ectrims.congress.eu>ectrims; Berlin, Germany. 10 12, 2018:228889
  • Kimbrough D, Reyes-Mantilla M, Jimenez Arango J, Pardo-Villamizar C. Identifying multiple sclerosis in patients with systemic sarcoidosis (P06.214). Neurology. 2013;80(7 Suppl). P06.214.
  • Willis MD, Hope-Gill B, Flood-Page P, et al. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Mult Scler. 2018;24(13):1779–1782. doi:10.1177/135245851879039130307364
  • Graf J, Ringelstein M, Lepka K, et al. Acute sarkoidosis in a multiple sclerosis patient after alemtuzumab treatment. Mult Scler. 2018;24(13):1776–1778. doi:10.1177/135245851877127630307371
  • Carbonelli C, Montepietra S, Caruso A, et al. Monaldi. Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy. Arch Chest Dis. 2012;77(1):29–31.
  • Tebben PJ, Singh JR, Kumar R. Vitamin D-mediated hypercalcemia: mechnisms, diagnosis, and treatment. Endocr Rev. 2016;37(5):521–547. doi:10.1210/er.2016-107027588937
  • Kempisty A, Lewandowska A, Kus J. Disturbances of calcium metabolism and vitamin D supplementation in sarcoidosis. Two-way street. Pol Merkur Lekarski. 2018;44(261):147–149.29601566
  • Sodhi A, Aldrich T. Vitamin D supplementation: not so simple in sarcoidosis. Am J Med Sci. 2016;352(3):252–257. doi:10.1016/j.amjms.2016.05.02727650228
  • Conron M, Young C, Beynon HL. Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford). 2000;39:707–713. doi:10.1093/rheumatology/39.7.70710908687
  • Miedema JR, Kaiser Y, Broos CE, Wijsenbeek MS, Grundewald J, Kool M. Th17-lineage cells in pulmonary sarcoidosis and Löfgren`s syndrome: friend or foe? J Autoimmune. 2018;87:82–96. doi:10.1016/j.jaut.2017.12.012
  • Kamphuis LS, Bonte-Mineur F, van Laar JA, van Hagen PM, van Daele PL. Calcium and vitamin D in sarcoidosis: is supplementation safe? J Bone Miner Res. 2014;29(11):2498–2503. doi:10.1002/jbmr.226224753153
  • Hoepner R, Bagnoud M, Pistor M, et al. Vitamin D increases glucocorticoid efficacy via inhibition of m TORC1 in experimental models of multiple sclerosis. Acta Neuropathol. 2019. doi:10.1007/s00401-019-0218-8
  • U.S. National Library of Medicine. Vitamin D homeostasis in Sarcoidose. Available from: ClinicelTrials.gov. Identifer: NCT03621553.
  • Escasany AA. Reporting suspected adverse reactions to new commercialized medicines in real world. Mult Scler. 2018;24(6):816–817. doi:10.1177/1352458518754999 29359623
  • Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–281. doi:10.1056/NEJMra07055317634462
  • Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88(2):582S–586S. doi:10.1093/ajcn/88.2.582S18689406
  • Martyn-Dow B, Briggs FB. Characterizing polyautoimmunity and familial autoimmunity in a U.S. multiple sklerosis population. Mult Scler. 2019;25(1 Suppl):20–156. ACTRIMS 05. 07.2019,biostatisticsP027. doi:10.1177/1352458519843086

Reference

  • Gaither CC, Cavazos-Gaither AE Gaither`s Dictionary of Scientific Quotations. Springer Science & Business. Media 2008, page 361.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.